Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study

Lu, J; Fu, WJ; Li, W; Hu, JD; An, G; Wang, YF; Fu, CC; Chen, LJ; Jin, J; Cen, XN; Ge, Z; Cai, Z; Niu, T; Qi, M; Sun, S; Gai, X; Liu, WP; Liu, WY; Yang, X; Huang, XJ

Huang, XJ (corresponding author), Peking Univ, Collaborat Innovat Ctr Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp, Xizhimen South St, Beijing 100000, Peoples R China.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021; 21 (9): E699

Abstract

Daratumumab plus bortezomib/dexamethasone (D-Vd) significantly improved outcomes versus Vd in patients with relapsed or refractory multiple myeloma (R......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索